Halbjahresbericht 2024 and Fortschritte at ExoPTEN

Frankfurt (pta004/08.09.2024/09:30 UTC+2)

NurExone Biologic Inc., an operating biopharmaceutical company, has made financial and financial investments for the second quarter of 2024. If you are looking for a regenerative medicine therapy concept, the recovery of the exoPTEN drugs is possible.

Company Highlights
Association with Vivox Ltd.: On April 1, 2024, NurExone entered into a partnership with Vivox Ltd. for animal studies to test the safety and effectiveness of ExoPTEN. These studies were conducted based on an investigational new drug (IND) application with the FDA, with clinical trials beginning in early 2025.
Notification: On April 25, 2024, NurExone’s parent company was announced under the symbol “NRXBF” on the Pink Sheets platform. On May 6, 2024, the Hochstufung of OTCQB Venture Market took place, the establishment of the company in the Finanzwelt. The DTC-Zulassung is active in the trading liquidity of Aktien.
Extension of patent protection: Am 11. June 2023 Erhielt NurExone a Patenterung in Japan for ExoPTEN, was the Marktzugang in Fernen Osten stärkt.
Advisory association: On June 21, 2024, Dr. Yona Geffen intervened as a consultant, performed a clinical and clinical activity with us. Dr. Geffen brought 20 years of research in Arzneimittelentwicklung with.

Financial results Q2 2024
Research and development: F&E costs have increased to USD 0.51 million, compared to USD 0.46 million in the future, higher subcontractor and material costs.
General processing costs: These costs amount to USD 0.81 million and are provided by higher expenditures on professional services.
Financing terms: A net surplus of USD 1.33 million would be earned with USD 1.04 million in the future.
Liquidity: On June 30, 2024, NurExone was purchased for USD 2.39 million, a purchase of USD 0.54 million since December 2023. This purchase results in a large private market and the purchase of options.

Prospect

NurExone has a regulatory deadline for 2024, a statement of the recovery processes on a GMP-compliant version. Dr. Yona Geffen started as a new research into the commercial approach. The collaboration with the Goldschleger Eye Institute for the analysis of ExoPTEN on the glaucoma market said that there were many spreading results. The external system can focus on the further development of research and development, so that the preparation of ExoPTEN for clinical study and commercial recovery arises. The design plan is strategic in nature, a permanent waiting list and a long-term experience with recommended results.

———-

Welding I in the Verteiler für NurExone Biological of Nebenwerte eintragene. Send an email to Eva Reuter: [email protected] with the Hinweis: “Verteiler NurExone” or “Nebenwerte”.

NurExone Biologic Inc.
ISIN code: CA67059R1091
https://nurexon.com
Country: Israel and Canada

Sources:
¹https://www.boerse.de/nachrichten/IRW-News-NurExone-Biologic-Inc-NurExone-kuendigt-die-Uebertragung-der-Herstellung-des-aktiven-Elements-im-ExoPTEN-Medikament-an-einen- kommerziellen-GMP-Hersteller-an/36334558
²https://xcelerator.siemens.com/global/en/industries/pharmaceutical-life-science-industries/pharma-industry/good-manufacturing-practice.html

Disclaimer/Risk limitation
Interesting information: NurExone Biologic consists of an extended IR and PR version. If you turn on the conscription, the degree of the onternehmens is at high altitude. Dr. Reuter Investor Relations dealt with the development and expansion of articles in interest of NurExone Biologic. It is a matter of a verifiche redaktionelle Darstellung. Aktien van NurExone Biologic has made a decision on the Mitarbeitern or Autoren von Dr. Reuter Investor Relations – under the supervision of the rules of the Market Abuse Regulation (MAR).

Company risks: The risks that each company has are focused on the conversion of the business model. It is not that the design model makes the plans a lot easier. We repeat a number of risks of NurExone that the prospect can use to start https://nurexone.com/investors/ download is possible.

Investment risks: Investments will now be carried out with half the time, which are free of research and are not used for the security of the livelihood. It is not certain that an article from the last century is worth using the time point. Grundsätzlich unterliegen Aktien under the risks of a total indulgence.

Disclaimer: All in this Newsletter / Article available Information for further research. This information does not constitute a Verkaufsangebot for the discussed Action(s) nor an Aufforderung zum Kauf or Verkauf von Wertpaperen dar. The Ausführungen lie Quellen zgrunde, die der Herausgeber für trauenswürdig erachtet.

Questions: Insofar as the research and analysis of the social information and the external information website are relevant. As a rule, it is best to contact the Vorstand / IR Team of the analysis instruments bzw. vorgestellten Gesellschaft. The article would be the NurExone Biological-vorgelegt, a guideline for all types of uses.

Future-oriented excursions
This Mitteilung enthält bestimmte zkunftsgerichtte Aussagen, einschließlich Aussagen über das Unternehmen. We are always more than happy to know what we are talking about: we can understand it, are able to do it, solve it, know it, understand it, plan it, look at it, look at it, look forward to it, look forward to it, look forward to it and look forward to it or “potenziell” or the Verneinung or other Variationen die Wörter or ähnliche Wörter or Phrasen used, een diese zukunftsgerichteten Aussagen zu identifizieren. These Aussagen reflect the gegenwärtigen Einschätzungen of the authors more broadly and based on information, the autor zum Zeitpunkt der Veröffentlichung dieses Berichten vorlagen.

Future-oriented statements are associated with real risks, uncertainties and uncertainties. Many factory settings can be carried out if the actual errors, achievements or failures are abwechen from the errors that are or were implied in the future-oriented statements. These factory towers are often monitored and the reader is no longer able to go on the future-oriented statements. If you get started with the authorization during the press conference on Annahmen, learning cannot be assured that the actual ones are very good with those future-oriented statements-over-instimmen. Dr. Reuter Investor Relations is not obligated, these Aussagen are active or active, a new Ereignissen or Umstandden Rechnung of slow, so that there is no question of a writing.

Verantwortlich & Kontakt für Rückfragen
Small & MicroCap investments through Dr. Reuters Investor Relations
Dr. Eva Reuter
Friedrich-Ebert-Anlage 35-37
60327 Frankfurt
+49 (0) 69 1532 5857
www.dr-reuter.eu
www.small-microcap.eu

Für Fragen bitte Nachricht an [email protected]

(End)